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Solute carrier (SLC) membrane transport proteins control essential physiological functions,
including nutrient uptake, ion transport, and waste removal. SLCs interact with several important
drugs, and a quarter of the more than 400 SLC genes are associated with human diseases. Yet,
compared to other gene families of similar stature, SLCs are relatively understudied. The time is
right for a systematic attack on SLC structure, specificity, and function, taking into account kinship
and expression, as well as the dependencies that arise from the common metabolic space.Individual cells, be they prokaryotic or eukaryotic, must control
chemical exchange with their environments, and they use lipid
membranes and proteinaceous channels and transporters to
this end. The lipid environment of the membrane prevents intru-
sion or leakage into the sancta sanctorum of the inner milieu and
buffers the cell against changing and noxious environmental
conditions, as well as against attack by phages, viruses, or bac-
teria (Ko¨berlin et al., 2015; Mulkidjanian et al., 2009). In many re-
spects, the integrity of the membranes represents as critical an
element to cellular individuality as does the preservation and
transmission of genetic information (Schrum et al., 2010). The
protein components of cell membranes import and export
most of the chemical matter essential for life, including water,
ions, gases, nutrients, vitamins, cofactors, and many drugs
(Kell et al., 2011; Kell andOliver, 2014; Lin et al., 2015). Therefore,
regulation of small-molecule transport across membranes is key
to a cell’s internal physiology and is the gatekeeper to its inter-
face with the environment (Nigam, 2015). Yet, despite their cen-
tral role in mediating the discussion between chemistry and
biology and despite the fact that 10% of the human genome
encodes for transport-related functions (Hediger et al., 2013),
transporters, as a class of proteins, do not appear to garner quite
the attention that they deserve.
Transporters comprise solute carriers, ion channels, water
channels, and ATP-driven pumps, including ABC transporters.
Of these, the largest group is formed by the solute carrier pro-
teins (SLCs), which according to the current counting comprises
456 members, distributed in 52 subfamilies that can be further
phylogenetically grouped (Hediger et al., 2013, 2004; Schles-
singer et al., 2010, 2013b). SLCs are membrane integral proteins
localized on the cell surface and in organellar membranes and
comprise facilitative transporters, which are equilibrative, and
secondary active transporters (symporters and antiporters),478 Cell 162, July 30, 2015 ª2015 Elsevier Inc.which may be concentrative (Hediger et al., 2013). After G-pro-
tein-coupled receptors (GPCRs), SLCs are the second-largest
family of membrane proteins in the human genome (Hoglund
et al., 2011). For detailed information about the individual SLC
family members, please refer to www.bioparadigms.org.
Links to Therapeutics and Human Disease
Much research on SLCs has been spurred by their relevance to
pharmacology and drug discovery, either as drug targets them-
selves or as mediators of drug disposition. Drug targets include
SLC6A4 (SERT), the target of the hugely important serotonin up-
take inhibitor drug class. Mediators of drug transport include
SLCO1B1, which transports statins and allows for preferential
drug distribution into the liver compared to other tissues, such
as muscle. This tissue distribution of statins is important in
driving their therapeutic index by increasing the lipid lowering
over the myopathy-causing activity (Giacomini et al., 2010).
SLC-mediated transport of statins and other drug classes can
also render their pharmacokinetics susceptible to drug-drug in-
teractions. For example, naringin from citrus fruits inhibits the
enterohepatic transporter SLCO1A2 and thus can reduce the
bioavailability of drugs that rely on this transporter, such as fexo-
fenadine (Bailey, 2010). Transport canalsobeaffectedby thenat-
ural pharmacogenomic variability in SLCs (Giacomini et al.,
2013). Other SLCs have been studied for their roles in physiology,
like SLC25A7 (UCP1), the mitochondrial uncoupling protein
involved in the thermogenesis process of brown adipose tissue.
Newer research has implicated SLCs in the action of chemo-
therapeutics; YM155, a cancer drug in clinical evaluation, was
found to be completely dependent on SLC35F2 for entry into
human tumor cells (Winter et al., 2014). Increasingly, SLCs are
attracting attention because they mediate drug-drug and
nutrient-drug interactions. For instance, the investigational
Figure 1. SLCs Are the Most Neglected
Group of Genes in the Human Genome
(A) Publication asymmetry is plotted against the
average number of publications per group of
genes. Publication counts per gene were retrieved
from the gene2pubmed file provided and curated
by NCBI. Gene groups comprise all HGNC gene
families and super-families as well as the GO an-
notations for kinase activity (‘‘kinases’’) and ion
channel activity (‘‘ion channels’’). Asymmetry is
measured for each group of genes by calculating
the skewness (as implemented in R’s ‘‘moments’’
package) of the distribution of the number of
publications for all genes within the group. A very
positive skew thus indicates an uneven distribu-
tion where a few genes in the family concentrate a
much higher number of publications than the rest.
Dot size relates to the number of members in each
gene group, and color indicates gene groups
where at least 80% of their members are anno-
tated as membrane proteins by GO annotation
(see legend). Labels for selected classes are
shown.
(B) Number of publications per SLC gene is dis-
played in descending order. The four SLCs with
the most publications are annotated. The red line
indicates the border at which genes have fewer
than 15 publications.JAK2 inhibitor fedratinib, which was recently terminated from
development due to incidence of Wernicke’s encephalopathy
during trials, has been shown to inhibit thiamine uptakemediated
by SLC19A2 (hTHTR2), possibly contributing to the offside ef-
fects (Zhang et al., 2014). It would not be surprising if further un-
planned SLC-drug interactions were uncovered in the future.
There is also growing interest in SLCs because of their clear
genetic link to human diseases; about 190 different SLCs have
been found mutated in human disease and through genome-
wide association studies (Williams et al., 2012, 2014).
Are SLCs Getting the Attention They Deserve?
Our sense was that the SLC protein family, despite its clear rele-
vance to health and disease, was comparatively less well studied
than other gene families. In an attempt to quantify ‘‘SLC knowl-
edge’’ versus other gene families, we surveyed the literature
and analyzed the distribution of publications as reported by
NCBI for each gene family annotated by HGNC in an automated,
unbiased fashion (Bruford et al., 2008). We then visualized the
publication asymmetry, defined by the coefficient of skewness,
versus the average number of publications for each family (Fig-
ure 1A). SLCs show by far the greatest publication asymmetry
of all gene families, i.e., the most uneven distribution of papers
over the group members. This does not seem to be simply due
to a bias against membrane proteins in general, as ABC proteins,
ion channels, and GPCRs appear not so unevenly distributed.
Further, SLCs have an average number of publications permem-
ber of around 35, which is half of what is observed on average
over all families (66 publications). At the other end of the spec-
trum, one finds, among others, that the small TNF superfamily
of ligands are all equally and very well studied.We then analyzed the asymmetry within the SLC knowledge
domain. We performed an automated search for publications
per each of the 456 SLC genes (including 65 pseudogenes),
which indeed displayed a highly skewed SLC knowledge distri-
bution curve (Figure 1B). A manually annotated search revealed
the same general pattern (Figure S1B). Both analyses reveal that
some gene members are extremely well studied, whereas most
have very few publications. In a phenomenon that appears to be
general to all human protein families, themost well-studied SLCs
in the last 2 years are almost identical to those that were themost
well studied a decade ago (Edwards et al., 2011). Prior to 2003,
20 of the 400 SLC family members accrued 29% of the publi-
cations for the entire family, and those exact same family mem-
bers garnered 32% of all SLC publications over the period 2012–
2014 (Figure S1A).
Rankings of the SLC family members do not seem to be indic-
ative of biological relevance. Some of the most well-studied
SLCs appear to have become objects of investigation simply
due to their abundance and tissue-specific expression in easily
isolated cell types, which greatly facilitated their study in the
era before molecular biology. Examples of this type include the
so-called ‘‘band 3 of erythrocytes’’ protein (SLC4A1) and
the erythrocyte glucose transporter GLUT1 (SLC2A1).
An important factor that contributes to the elevated publica-
tion rate of particular transporters has been expression cloning.
In the case of the intestinal Na+-glucose transporter SGLT1
(SLC5A1), due to its hydrophobic nature and difficulty in purify-
ing, functional expression in Xenopus laevis oocytes finally
opened the door to successful cloning and molecular character-
ization (Hediger et al., 1987). This progress led to a substantial
increase in SLC study, ultimately leading to structuralCell 162, July 30, 2015 ª2015 Elsevier Inc. 479
Table 1. SLCs Specifically Targeted by FDA-Approved Drugs or
Drugs in Active Development
Drug Status SLC
Common
Protein
Name Examples
Approved SLC5A2 SGLT2 canagliflozin;
dapagliflozin
SLC6A1 GAT1 tiagabine
SLC6A2 NET atomoxetine
SLC6A3 DAT methylphenidate
SLC6A4 SERT fluoxetine; sertraline;
citalopram (SSRIs)
SLC12A1/2 NKCC1/2 furosemide (loop
diuretics)
SLC12A3 NCC hydrochlorothiazide
(thiazide diuretics)
SLC18A1/2 VMAT1/2 reserpine
SLC18A2 VMAT2 tetrabenazine
SLC22 family OATs probenecid
SLC25A4/5/6 ANT1/2/3 clodronate
SLC29A1 ENT1 dipyridamole
Phase II+
Clinical Trial
SLC5A1
(and SLC5A2)
SGLT1
(and SGLT2)
sotagliflozin
SLC6A9 GlyT1 bitopertin
SLC9A3 NHE3 tenapanor
SLC10A2 IBAT elobixibat
SLC22A12 URAT1 lesinurad
SLC40A1 Ferroportin-1 LY2928057determination (Faham et al., 2008) and development of an antidi-
abetic drug class (Abdul-Ghani and DeFronzo, 2014) that acts on
its renal homolog SGLT2 (SLC5A2).
Other SLCs became highly studied because they were discov-
ered as targets of existing drugs, with VMAT2 (SLC18A2) repre-
senting a specific example of this. Reserpine is a drug that was
first marketed in the 1950s as a tranquilizer. The actual mode
of action of reserpine was only uncovered 40 years later by
scoring for cDNAs conferring the ability to sequester the neuro-
toxin 1-methyl-4-phenylpyridinium (MPP+) in CHO cells, leading
to the discovery of the vesicular amine transporter family SLC18
(Liu et al., 1992). As an example of how the availability of
research tools has influenced SLC research, there were no pub-
lications at all on SLC30A8 until its first cloning and expression in
2004 (Chimienti et al., 2004). Following this publication and a se-
ries of papers genetically linking mutations in this protein with
diabetes, in recent years SLC30A8 has become one of the
most highly studied SLCs (Rutter and Chimienti, 2015). This
spike of activity is clearly displayed in Figure S1A. Even more
recently, some SLCs that were previously barely studied have
been identified to play key roles in physiology. SLC38A9, an
SLC recently found to contribute to amino-acid sensing of
mTOR, was ranked 288th in the automated ranking of all time
SLC publications (Rebsamen et al., 2015; Wang et al., 2015).
With the importance of this SLC now clear and tools available
to allow its study, one can anticipate an increase in publication480 Cell 162, July 30, 2015 ª2015 Elsevier Inc.rate for this transporter. As for the bottom-ranked 15% of SLC
family members, there are more publications in a PubMed
search for ‘‘star wars’’ (72 citations) than on these 70 SLCs
combined.
Exploring SLCs as Drug Targets
Regarding SLCs as drug targets, a recent publication suggests
26 different SLCs being the targets of known drugs, or drugs in
development (Lin et al., 2015; Rask-Andersen et al., 2013). A
closer inspection using more stringent criteria (FDA-approved
drugs whose primary mode of action is considered to be through
action on an SLC) revealed just 12 drug classes. Only 8 of these
drug classes are believed to act through selective action at a sin-
gle SLC, while 4 classes are believed to act non-selectively via
two or more SLCs. Only 6 further SLCs are targeted by drugs
in active development in phase II clinical trials or beyond
(Table 1). Several drugs interact with SLCs in addition to their
purported primary target, e.g., amiloride (SLC9A1, NHE1) or sul-
fasalazine (SLC7A11, xCT), but in such examples, it has not been
clearly established that these effects contribute to their clinical
pharmacology. The GPCR family, in contrast, is a well-estab-
lished drug target class that has been the subject of systematic
drug discovery efforts for half a century. Even when considering
the possibility that GPCRs may be intrinsically more relevant as
drug targets, the difference between a fewSLC targets and100
GPCR targets is likely to reflect a historical bias. Clearly the SLC
family is underexplored from the standpoint of drug discovery.
Druggability of SLCs appears not to be the main or only barrier
here, as the majority of the well-studied SLCs have reported
small-molecule inhibitors.
Is it reasonable to expect more SLC-targeting drugs? Around
75% of SLCs are predicted to carry small organic molecules. It
has been proposed that proteins that have evolved to bind
such species are, on average, privileged with respect to small-
molecule druggability (Fauman et al., 2011). Experiences thus
far appear to support this prediction, with molecules of high
ligand efficiency (an indicator or protein druggability) (Hopkins
et al., 2014) being identified in the cases where medicinal chem-
istry efforts have been attempted against SLCs. Even SLCs that
carry only inorganic species have been shown to be druggable,
including, for example, the SLC12 family targets of the loop and
thiazide diuretics. Thus, SLCs appear to offer the rare potential of
an underexplored gene family with high disease relevance and
general small-molecule druggability.
SLC Genes and Human Disease
Current thinking in biomedicine and drug discovery contends
that human genomics will provide the clues to those genes and
proteins of particular relevance to disease and therapy. Accord-
ingly, we looked at all SLC genes that are associated with human
disease and counted the number of compounds reported for
each (IC50 < 10 mM), using OpenPHACTS, a platform that pro-
vides a single access to disease, chemical, and target databases
(Ratnam et al., 2014; Williams et al., 2012). 76% of SLCs (145 out
of 190) with an already identified disease link have no compound
associated with them (Figure S2). It is notable how few SLC tar-
gets have more than 100 active compounds against them in the
database, likely to represent another measure indicative of how
few drug discovery programs have been run against the family. In
contrast, the most popular targets of monoamine uptake inhibi-
tors (SLC6A2,3,4) have more than a thousand compounds asso-
ciated with each, with likely thousands more such compounds in
pharmaceutical company collections as a result of extensive
drug discovery campaigns against these targets.
Of course, it could be argued that involvement of SLC genes in
monogenic disorders is a poor reason to call for drug discovery
efforts in the corresponding disease areas, as it appears coun-
terintuitive. Yet such arguments need not be always valid, as
there is a fundamental difference between life-long genetic
loss of function (LOF) and the titrated, reversible pharmacolog-
ical blockade of a protein. For instance, LOF mutations in the
dopamine transporter SLC6A3 lead to early stage Parkinsonism
disease (Kurian et al., 2009), but SLC6A3 is also a principal target
of methlyphenidate and in the treatment of psychiatric disorders.
Further, LOFmutations in SLC12A3 have been found associated
with Gitelman’s syndrome, characterized by low blood pressure,
and SLC12A3 could bemechanistically linked to the action of thi-
azides that treat hypertension (Brinkman et al., 2006). Even if we
take a more stringent connection to disease by counting only the
genetic mutations in the OMIM database (103 different SLCs)
(Amberger et al., 2015), it is clear that the ‘‘disease’’ zones of
the SLC network are not covered nearly enough by chemical
agents.
Why So Little Research Attention Then?
Whatmight have contributed to this apparent anomaly in the dis-
tribution of research attention for the SLC gene family, where
somemembers are well studied and somanymembers not stud-
ied at all? First, a unifying nomenclature has been adopted only
recently (Hediger et al., 2013, 2004), and as a consequence,
common principles and features may have been overlooked.
Second, there are a number of technical barriers that may have
impeded research in this area. In particular, acquiring competent
biological reagents for SLC study can be highly challenging.
These are complex integral membrane proteins that are difficult
to express and purify and are often poorly detected by typical
protocols for mass spectrometry. Accordingly, biochemical, bio-
physical, and structural biology characterization of SLCs has
also been challenging. Indeed, there are so far only three re-
ported human SLC structures (Deng et al., 2014; Gruswitz et al.,
2010; Schlessinger et al., 2013a; Deng et al., 2015) (Table S1).
Cell-based systems for studying SLC function can likewise be
challenging to obtain, as overexpression can cause toxicity
(presumably as a result of metabolic perturbation), and loss- or
gain-of-function studies can be confounded by endogenous
SLCs with overlapping specificities or by compensatory trans-
port or metabolic effects. Even when cell systems with function-
ally competent SLCs can be obtained, defining their relevant
endogenous substrates is not trivial, and establishing screening
assays can be difficult. Third, high-quality antibodies are avail-
able for only a few SLCs, with the human protein atlas reporting
just 45 SLCs for which they have raised reliable antibodies (Uhlen
et al., 2015). As a consequence, the current understanding of the
subcellular localization of SLCs, crucial for the interpretation of
their function, is indeed partial at best. Finally, the transport
assays are often challenging, even for those SLCs with knownsubstrates. Artificial lipid vesicles or microinjected frog oocytes,
two other useful assay systems, do not necessarily allow for
testing function in the context of the regulatory intricacies, and
the latter is not always robust enough for large-scale compound
screening. In short, despite the post-genomic era, ample
evidence for their important physiological role and their drugg-
ability, the systematic and parallel structural and functional inter-
rogation of human SLC proteins has not yet been carried out.
Delving into the ‘‘Sparse Zones’’ of Our Knowledge
Here, we argue that an energetic and detailed exploration of the
human ‘‘SLCome’’ is warranted because the family comprises
one of the largest ‘‘sparse zones’’ of human biology. Indeed,
the concept of the rational filling of sparse zones of knowledge
is starting to guide strategies in other collaborative efforts (Roll-
and et al., 2014; Snijder et al., 2014). Furthermore, we argue that
the problem should be tackled systematically to capture the
efficiencies that come with economies of scale and the learnings
that derive from studying related proteins. Finally, we believe that
the initial objective of this effort should focus on generating high-
quality, enabling reagents (antibodies, purified proteins, cell-
based assays, chemical probes, CRISPR-cell lines) and data
sets (protein interaction, tissue and sub-cellular distribution).
Such a concerted effort is not only called for but is also timely
due to recent technological developments, listed and referenced
in Table 2. Such developments cover protein expression, metab-
olomics, structure determination, gene knockout technologies,
and mass spectrometry, as well as assay development and me-
dicinal chemistry, to deliver high-quality chemical tools into the
public domain. We listed possible project aims of a concerted
campaign, fully aware that such lists are not comprehensive
and are meant to spur additional thoughts. There are several ex-
amples of successful de-orphanization of SLCs using recently
developed technologies (Abplanalp et al., 2013; Caulfield et al.,
2008; Iharada et al., 2010; Rebsamen et al., 2015; Wang et al.,
2015; Wikoff et al., 2009; Winter et al., 2014).
In broad terms, the strategy to study proteins by family, where
experimental methods on one familymembermay facilitate anal-
ysis of the next (Hoglund et al., 2011; Schlessinger et al., 2010),
has been highly successful for tackling the structure and chem-
ical tractability of other gene families such as kinases, GPCRs,
and proteins involved in the regulation of the epigenome (Barr
et al., 2009; Edwards et al., 2009). Importantly, although one
would expect similar success applying this approach to the
SLC family, there is an additional opportunity that functional in-
ter-relationships among SLCs, on top of phylogeny, may greatly
aid in the design of the experimental strategy.
Working Groups of SLCs
It is highly likely that the transport activity of one SLC may affect
the activity of others, acting in parallel or in sequential order, in
redundant or interdependent function, integrating with the
cellular metabolism in various ways (Nigam, 2015; Thiele et al.,
2013). If this is the case, there may be several ways to uncover
such functionally linked groups, for example, by analyzing co-
expression patterns (Huynen et al., 2003; Jordan et al., 2004;
Stuart et al., 2003). Proteins acting together are more likely to
be co-expressed across tissues and conditions than if they areCell 162, July 30, 2015 ª2015 Elsevier Inc. 481
Table 2. Approaches to Enable SLC De-orphanization
Objective Enabling New Technology References
Expression map of SLCs across the human
body, at single-cell and sub-cellular
resolution
large-scale RNA-seq; single-cell RNA-seq;
expression proteomics and antibody
mapping efforts; MALDI imaging mass
spectrometry; CyTOF
(Bendall et al., 2011; Clemencon et al.,
2015; Cornett et al., 2007; Kim et al., 2014;
Mele et al., 2015; Uhlen et al., 2015; Wilhelm
et al., 2014)
Human cell lines mutated in individual SLC
genes
CRISPR technology; insertional
mutagenesis in haploid cells
(Burckstummer et al., 2013; Carette et al.,
2009; Doudna and Charpentier, 2014)
Cell lines with multiple SLC gene deletions;
cells with minimal SLC repertoire
CRISPR-mediated genomic engineering (Doudna and Charpentier, 2014; Hsu et al.,
2014)
SLC genetic interaction landscape SLCome- and genome-wide CRISPR
inactivation and gain of function libraries;
k.o. cells
(Cong et al., 2013; Qi et al., 2013)
Chemical genomics high-throughput phenotypic screening (Carette et al., 2009; Reiling et al., 2011;
Winter et al., 2014)
SLC interactome label-free high-throughput AP-MS;
BirA-mediated BioID; membrane
interaction mapping
(Cox and Mann, 2011; Lambert et al., 2015;
Petschnigg et al., 2014; Varjosalo et al.,
2013)
Metabolomic data and SLC genetic
polymorphisms
genetic association studies; population-
wide whole-genome sequencing; rare
disease genome sequencing coupled with
deep metabolomics
(Shin et al., 2014)
Metabolome-wide transport assays, in
dependence of individual SLC gene
alteration
high-throughput accurate LC/ GC-mass
spectrometry and databases; libraries of
metabolites; k.o. cells
(Kell, 2004)
Transport assays using recombinant
proteins
proteoliposomes; liposome microarrays;
pure solutes, complex body fluids
(Krumpochova et al., 2012; Saliba et al.,
2014; Scalise et al., 2013)
High-throughput determination of 3D
structure
single-particle cryo-EM; high-throughput
crystallization protocols; serial
femtosecond crystallography
(Bai et al., 2015; Bartesaghi et al., 2015;
Chapman et al., 2011; Moraes et al., 2014;
Zeev-Ben-Mordehai et al., 2014; Zhou
et al., 2015)
Potent and selective chemical probes for
each SLC
better libraries; more accurate screening
technologies; assays to assess target
engagement and specificity in cells and
tissues
(Edwards et al., 2009; Frye, 2010)functionally independent. SLCs that are consistently identified to
be co-expressed and thus represent such putative working
groups or functional modules may, in turn, help to shed light
on the role of the individual family members. Perhaps these
connections can be used to distinguish an underlying overall ar-
chitecture, which might be suggestive of dependencies and vul-
nerabilities of the system.
To explore this concept more fully, we analyzed different gene
expression data sets of human tissues (Fantom5, Illumina body
map, and the ‘‘32 tissues’’; Forrest et al., 2014; Parkinson
et al., 2011; Uhlen et al., 2015) and derived a global and high-
confidence survey of patterns of co-expression across SLC
genes. These patterns for co-expression were analyzed to iden-
tify SLCs that are frequently and consistently co-expressed. Co-
expression relationships were ranked based on the combined
p values of the correlations in the three independent data sets
used. For visualization convenience, we chose to display only
the top 2,500 co-expressed SLCs observed in at least two
data sets. We found at least five major clusters and several
smaller ones, perhaps representing fundamental functional rela-
tionships (Figure 2A). The edges were colored according to the482 Cell 162, July 30, 2015 ª2015 Elsevier Inc.tissue in which two connected SLCs are most highly, but not
necessarily exclusively, expressed. We found that the clusters
correspond to individual tissues (kidney, liver, brain, testis, leu-
kocytes). Interestingly, kidney and liver seem to share the highest
number of co-expressed SLCs despite their different germ-layer
origin. A more fine-grained tissue annotation shows that the kid-
ney/liver intersection harbors the SLCs whose co-expression is
highest in intestinal tissue (Figure S3A). This similarity between
kidney and liver co-expression is specific for SLCs, as a recently
published genome-wide tissue expression comparison revealed
a considerably larger ‘‘distance’’ between these organs (Mele
et al., 2015).
The network displayed does not automatically reveal all text-
book cases of co-expression. For example, expression of
SLC26A4 (iodide transporter, pendrin) and SLC5A5 (sodium io-
dide co-transporter) is well known to be coordinately expressed
in thyroid tissue. While a significant level of co-expression is
observed in the thyroid, several tissues either express one or
the other, suggesting that they may not always be obligatory
partners and may have independent functions. Accordingly,
the correlation, although significant, did not reach the top
Figure 2. SLCs Are Expressed in Robust Tissue-Dependent Modules
(A) Network visualization of SLC co-expression. Nodes in the network represent SLCs. Edges between nodes correspond to significant correlations consistently
retrieved in three independent expression data sets from healthy human tissues. Only the top 2,500 most significant edges are shown, based on combined
p values of the three independent correlations. Gray nodes indicate SLCs with at least one disease association, and red node outlines indicate the presence of at
(legend continued on next page)
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2,500. To allow the interrogation of the full data set beyond what
can be reasonably visualized in a single network, we include an
extended list of SLC co-expression pairs across all tissues (Ta-
ble S2).
Not all SLCs are represented in the network because their
expression does not correlate strongly enough with any given
other to be among the top 2,500 that we chose to represent for
visualization. Of these SLCs, some 48 appear to be expressed
in all tissues and may thus represent a ‘‘core’’ of housekeeping
functions (Table S3). Membership to this group may make some
of them attractive to study for pharmacokinetic considerations.
We then looked at the distribution of disease-associated SLCs
across the network (dark gray filled nodes, Figure 2A). All clus-
ters (except the testis cluster) contain several positive SLCs,
confirming that SLC gene functions bear important pathophysi-
ological implications across many tissues and processes. The
SLCs for which high-affinity chemical agents have been devel-
oped are marked; their distribution was considerably less even
(red halos, Figure 2A). At least three cluster regions seem rela-
tively sparse in terms of drugs: heart and skeletal muscle, leuko-
cytes, and the intersection of liver and kidney. Perhaps these
regions merit more attention in the future.
The SLC families do not appear to group in clusters or tissues
(i.e., most SLC families appear distributed over the different
tissues), but there is a non-random pairing of co-expression be-
tween different SLC families whose pattern likely reflects meta-
bolic/biochemical dependencies (Figure 2B). For instance,
strong interaction between the SLC13 and SLC22 families is
likely to reflect an integration of energy and homeostatic regula-
tion of intermediate metabolism, particularly the Krebs cycle.
Enrichment in the interactions between families SLC5 (glucose
reuptake), SLC13 (citrate/dicarboxylate reuptake), and SLC47
(toxin/xenobiotic secretion) might be also explained by the role
of some of their members in kidney, where a coordinated trans-
port of their cargos is required. Furthermore, the sodium and
chloride symporter family SLC6, which transports monoamine
neurotransmitters and amino acid neurotransmitters, is heavily
linked with glutamate/neutral amino acid transporters of the
SLC1 family. This link suggests a connection at both a metabolic
and physiological level, especially important in brain tissue.
The robustness of SLC co-expression patterns across
different large-scale data sets was very high and clearly ex-
ceeded, for example, that of protein kinases (Figure S3B).
Possibly, SLC function has a particularly high degree of interde-
pendence reflective of the integrative nature of metabolism
required for homeostatic stability. The resulting co-expression
networks are likely to be reinforced by the integration with envi-
ronmental parameters.
The patterns of SLC co-expression may reflect normal cell
function; when we compared co-expression in different cancer
cell lines, we observed massive changes, corresponding to a
general loss of structural organization in the network. Theleast one interacting small compound with an IC50 below 10 mM (OpenPHACTS)
share the highest expression (highest mean rank; Illumina Body Map data set), a
(B) SLC family co-expression enrichment network. Nodes in the network repre
betweenmembers of the connected SLC families, as calculated by a hypergeome
is proportional to the number of co-expressed SLC pairs (see legend).
484 Cell 162, July 30, 2015 ª2015 Elsevier Inc.network of SLC co-expression in cancer is not robust, i.e., it is
not as reproducible across data sets, and it shows considerably
less clustering (Figure S3C). The degree by which cancer per-
turbs the SLC co-expression pattern is much higher than the dif-
ferences between normal tissues and cancer cell lines observed
with protein kinases.
Could loss of these ‘‘healthy’’ SLC co-expression patterns be
a good marker for the loss of homeostasis in certain diseases?
This analysis may suggest that there is a SLC regulatory circuitry
that may be crucial to medical and pharmacological consider-
ations and that might assist strategic choices in the effort to fill
the SLC knowledge gap. Armed with this knowledge, redun-
dancy and dependency are not annoying impediments of the
large SLC group but, rather, exploitable features.
Conclusions
In summary, SLCs are particularly understudied and fascinating
proteins, vital for correct cellular function by controlling the cor-
rect import andexport of themoleculesof life acrossmembranes.
They are important in disease and in the action and transport of
drugs. A broad attack on their structure, expression, regulation,
chemical structure-activity relationships, and functional charac-
terization in terms of transport and signaling is warranted. The
study of their regulation and interdependencies should be
particularly fascinating, as the functional target may be not only
a single protein but the vulnerability within the functional network,
perhaps involving ATP-dependent efflux transporters of the
ABC family as well. A full-force effort to study the ‘‘SLCome’’
would open the doors to the interface between human health
and metabolism, nutrition, and the environment. The large and
important family of SLCs should be neglected no longer.SUPPLEMENTAL INFORMATION
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